TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Merck Life Science AB
Closing information (x1000 EUR)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
116,118
|
118,864
|
90,862 |
| Financial expenses |
0
|
110
|
3 |
| Earnings before taxes |
63,166
|
63,894
|
60,352 |
| EBITDA |
59,679
|
63,562
|
60,344 |
| Total assets |
129,430
|
82,458
|
56,427 |
| Current assets |
128,183
|
81,129
|
49,029 |
| Current liabilities |
8,642
|
11,963
|
6,596 |
| Equity capital |
119,816
|
69,524
|
49,243 |
| - share capital |
928
|
926
|
1,007 |
| Employees (average) |
48
|
46
|
29 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
92.6%
|
84.3%
|
87.3% |
| Turnover per employee |
2,419
|
2,584
|
3,133 |
| Profit as a percentage of turnover |
54.4%
|
53.8%
|
66.4% |
| Return on assets (ROA) |
48.8%
|
77.6%
|
107.0% |
| Current ratio |
1483.3%
|
678.2%
|
743.3% |
| Return on equity (ROE) |
52.7%
|
91.9%
|
122.6% |
| Change turnover |
-3,092
|
35,362
|
17,908 |
| Change turnover % |
-3%
|
42%
|
25% |
| Chg. No. of employees |
2
|
17
|
0 |
| Chg. No. of employees % |
4%
|
59%
|
0% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.